Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
IPO Watch
Biological scaffold play Aroa Biosurgery surges 87pc on ASX debut
Health & Biotech
Osteopore shares fly after bagging new tech
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Who’s ramping things up today?
Health & Biotech
Osteopore cracks billion dollar US bone healing market, shares surge
News
10 at 10: These ASX stocks are blowing their trumpets this morning
Health & Biotech
Medtech needs more than a TGA tick to hit the big $$$
Health & Biotech
Australia’s TGA says ‘yes’ to Osteopore’s bone healing devices
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV
StockTalk: The beneficiaries of China’s economic bounce-back
News
There are signs China is getting back to work — here are 5 small caps which stand to benefit
Health & Biotech
Explainer: How Osteopore’s technology can ‘regrow’ bones
Health & Biotech
Medtech stocks are on the radar, and this analyst thinks the sector has further to run
Health & Biotech
Pick of the pods: Best of the Health Kick Podcast in 2019
News
The 10 ASX stocks that more than tripled in a single day in 2019
IPO Watch
IPO Watch: These are the top ASX debutantes of 2019
Escrow Watch